CCL3 and neoplasm: The myeloid chemoattractant CCL3 emerged as a significantly upregulated protein in the plasma of mice treated with aEGFRvIII-SGRP CAR, potentially shaping peripheral responses to local antitumor therapy, promoting antigen presentation in tumor-draining lymph nodes or inducing T cell proliferation and differentiation33.